Somac Control
Authorised
This medicine is authorised for use in the European Union
pantoprazole
MedicineHumanAuthorised
Overview
This is a summary of the European public assessment report (EPAR) for Somac Control. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Somac Control.
Somac Control is a medicine that contains the active substance pantoprazole. It is available as gastroresistant tablets (20 mg). ‘Gastroresistant’ means that the tablet’s contents pass through the stomach without being broken down until they reach the intestine. This prevents the active substance from being destroyed by the acid in the stomach. Somac Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Somac.
Somac Control is used for the short-term treatment of the symptoms of acid reflux in adults. Acid reflux is when acid produced in the stomach escapes into the gullet, causing heartburn and acid regurgitation (acid flowing up into the mouth).
The medicine can be obtained without a prescription.
The recommended dose of Somac Control is one tablet once a day until symptoms have stopped. The patient may need to take the medicine for two to three days in a row for symptoms to improve. If there is no improvement in symptoms within two weeks of continuous treatment, patients should consult their doctor. Patients should not take the medicine for longer than four weeks without consulting their doctor.
The tablets should be swallowed whole with liquid before a meal and should not be chewed or crushed.
The active substance in Somac Control, pantoprazole, is a proton-pump inhibitor. It works by blocking ‘proton pumps’, proteins found in specialised cells in the stomach lining that pump acid into the stomach. By blocking the pumps, pantoprazole reduces acid production, relieving the symptoms of acid reflux.
Pantoprazole-containing medicines have been available in the European Union (EU) since 1994. The reference medicine, Somac, is only available with a prescription. It is used for long-term treatments and is also used to treat a wider range of gastrointestinal diseases (conditions affecting the gut) than Somac Control.
Because pantoprazole has been in use for many years, the applicant presented data from the scientific literature. The applicant also presented information from two main studies looking at the effects of pantoprazole 20 mg in a total of 563 adults who had symptoms of acid reflux, including at least one episode of heartburn in the three days before the studies began. The first study compared pantoprazole with placebo (a dummy treatment) in 219 adults, and the second compared it with ranitidine (another medicine used to treat acid reflux symptoms) in 344 adults. The main measure of effectiveness was the number of patients with symptoms of heartburn over the first two weeks of treatment.
Pantoprazole was more effective than placebo and ranitidine at improving the symptoms of acid reflux. In the first study, 74% of the patients taking pantoprazole (80 out of 108) and 43% of those taking placebo (48 out of 111) had no heartburn after two weeks. Pantoprazole was also more effective than placebo at reducing symptoms of acid regurgitation. In the second study, 70% of the patients taking pantoprazole (121 out of 172) and 59% of those talking ranitidine (102 out of 172) had no heartburn after two weeks of treatment.
The most common side effects with Somac Control (seen in around 1 patient in 100) are diarrhoea and headache. For the full list of all side effects reported with Somac Control, see the package leaflet.
Somac Control must not be used in people who are hypersensitive (allergic) to pantoprazole, soya or any of the other ingredients. It must not be used with atazanavir (a medicine used to treat human-immunodeficiency-virus [HIV] infection).
The CHMP noted that pantoprazole 20 mg was effective in the short-term treatment of reflux symptoms and that there is a long safety experience with the medicine as a prescription medicine. It was also of the opinion that, based on the experience of the use of pantoprazole, the availability of Somac Control without medical supervision is appropriate. The CHMP therefore decided that Somac Control’s benefits are greater than its risks and recommended that it be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the EU for Somac Control on 12 June 2009.
For more information about treatment with Somac Control, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information: WS2321
26/04/2023
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Somac Control
- Active substance
- pantoprazole
- International non-proprietary name (INN) or common name
- pantoprazole
- Therapeutic area (MeSH)
- Gastroesophageal Reflux
- Anatomical therapeutic chemical (ATC) code
- A02BC02
Pharmacotherapeutic group
Proton pump inhibitorsTherapeutic indication
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Topics
This page was last updated on